Esperion Therapeutics shares are trading lower after the company announced that it entered into a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher, but it has since reversed.
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics shares are trading lower after the company announced a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher but has since reversed.
June 28, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Esperion Therapeutics shares are trading lower after the company announced a Royalty Purchase Agreement with OMERS Life Sciences. The stock initially traded higher but has since reversed.
The announcement of the Royalty Purchase Agreement initially caused a positive reaction in the stock price, but it has since reversed and is now trading lower. This suggests that investors may have concerns about the terms or implications of the agreement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100